VERUVERU INC.

Nasdaq verupharma.com


$ 1.26 $ 0.06 (4.96 %)    

Friday, 26-Apr-2024 15:59:04 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.27
$ 1.28
$ 0.00 x 0
$ 0.00 x 0
$ 1.22 - $ 1.28
$ 0.36 - $ 1.92
1,277,382
na
127.76M
$ 0.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-Q
2 12-08-2023 09-30-2023 10-K
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 02-09-2023 12-31-2022 10-Q
6 12-05-2022 09-30-2022 10-K
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 02-09-2022 12-31-2021 10-Q
10 12-02-2021 09-30-2021 10-K
11 08-12-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 02-10-2021 12-31-2020 10-Q
14 12-10-2020 09-30-2020 10-K
15 08-13-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 02-12-2020 12-31-2019 10-Q
18 12-12-2019 09-30-2019 10-K
19 08-08-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 02-13-2019 12-31-2018 10-Q
22 12-13-2018 09-30-2018 10-K
23 08-14-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 02-14-2018 12-31-2017 10-Q
26 01-02-2018 09-30-2017 10-K
27 08-09-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 02-09-2017 12-31-2016 10-Q
30 12-12-2016 09-30-2016 10-K
31 07-28-2016 06-30-2016 10-Q
32 04-28-2016 03-31-2016 10-Q
33 02-02-2016 12-31-2015 10-Q
34 12-02-2015 09-30-2015 10-K
35 07-30-2015 06-30-2015 10-Q
36 04-30-2015 03-31-2015 10-Q
37 02-03-2015 12-31-2014 10-Q
38 12-02-2014 09-30-2014 10-K
39 07-31-2014 06-30-2014 10-Q
40 05-01-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 cisco-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 oppenheimer-reiterates-outperform-on-veru-lowers-price-target-to-5

Oppenheimer analyst Leland Gershell reiterates Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $7 to $5.

 why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

 raymond-james-initiates-coverage-on-veru-with-outperform-rating-announces-price-target-of-3

Raymond James analyst Gary Nachman initiates coverage on Veru (NASDAQ:VERU) with a Outperform rating and announces Price Tar...

 hc-wainwright--co-reiterates-buy-on-veru-maintains-2-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Veru (NASDAQ:VERU) with a Buy and maintains $2 price target.

 veru-q1-sales-210m-miss-520m-estimate

Veru (NASDAQ:VERU) reported quarterly sales of $2.10 million which missed the analyst consensus estimate of $5.20 million by 59...

 earnings-scheduled-for-february-8-2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share ...

 veru-announces-fda-clearance-of-ind-application-for-phase-2b-clinical-trial-with-enobosarm-to-treat-muscle-loss-associated-with-weight-loss-drugs

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially ...

 veru-inc-13g-filing-shows-adage-capital-partners-lp-reported-a-95-stake-in-the-co-as-of-december-14-2023

- SEC Filing

 veru-to-host-investor-call-on-january-4th-2024-to-discuss-recent-financing-and-strategy-to-prioritize-the-development-of-enobosarm-as-a-combination-treatment-to-prevent-muscle-loss-and-augment-fat-loss-associated-with-weight-loss-glp-1-drugs

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatmen...

 veru-announced-today-the-pricing-of-an-33m-underwritten-public-offering-of-45833333-shares-of-its-common-stock-at-a-price-to-the-public-of-072share

Veru intends to use the net proceeds from the offering to fund its clinical stage drug development with a primary near-term foc...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION